Nucleic Acid-Lipopolymer Compositions for Stable Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Synthetic gene delivery systems face challenges with poor stability and low transfection efficiency due to DNA aggregation, especially at high concentrations required for clinical applications, limiting their commercialization and efficacy.
Innovation Solution
The development of stable and concentrated pharmaceutical compositions comprising a mixture of nucleic acid and cationic lipopolymer, where the cationic lipopolymer includes a polyethyleneimine backbone with cholesterol and polyethylene glycol groups, allowing for high nucleic acid concentrations without aggregation or loss of biological activity, enabling efficient lyophilization and reconstitution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If DNA formulations are prepared at high concentrations for optimal clinical dosing, then dosing flexibility and volume constraints are improved, but DNA aggregation occurs reducing transfection activity
Solution Approach 1:
The patent introduces cationic lipids as intermediary substances that mediate between DNA molecules to prevent aggregation. These lipids form stable complexes with DNA at high concentrations, acting as a protective intermediary layer that maintains transfection activity while enabling concentrated formulations for clinical dosing.
Solution Approach 2:
The patent creates composite material systems combining DNA with cationic lipids to form stable complexes. This composite approach allows the formulation to maintain both high DNA concentration and transfection activity by integrating the stabilizing properties of lipids with the therapeutic function of DNA.
2Duration of action of stationary object
If freeze-drying is used to improve long-term stability of DNA complexes, then shelf life is improved, but physicochemical properties are altered resulting in aggregation and loss of transfection activity
Solution Approach 1:
The patent applies preliminary protective actions by incorporating stabilizing excipients and optimizing formulation composition before the freeze-drying process. This preliminary stabilization prevents the aggregation and transfection loss that typically occur during lyophilization, allowing long-term storage without compromising activity.
Solution Approach 2:
The patent modifies formulation parameters such as pH, buffer composition, and excipient selection to optimize the freeze-drying process. By changing these parameters, the formulation maintains stability during lyophilization and upon reconstitution, preserving transfection activity while achieving long-term shelf life.
3Duration of action of stationary object
If lyophilization is performed with high sugar/DNA molar ratio for stability, then formulation shelf life is improved, but final DNA concentration drops to pre-lyophilized levels requiring large dilution volumes
Solution Approach 1:
The patent uses sugar excipients as protective copies or analogs that mimic the stabilizing environment needed for DNA during freeze-drying. These sugar molecules form a protective matrix that preserves DNA structure without requiring excessive amounts, thereby maintaining both shelf life and final DNA concentration.
Solution Approach 2:
The patent optimizes the sugar/DNA ratio and selects specific sugar types to achieve stability with minimal dilution. By changing formulation parameters and using optimized excipient combinations, the patent maintains high final DNA concentrations after reconstitution, enabling small-volume local administrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions achieve unexpected stability and increased dosing flexibility, maintaining biological activity and transfection efficiency even at high nucleic acid concentrations, overcoming previous limitations in synthetic gene delivery systems.
Implementation Method 1
pharmaceutical compositions comprising a mixture of nucleic acid and cationic lipopolymer
Implementation Method 2
Freeze-drying is a useful method for improving long-term stability of a number of drug pharmaceuticals
Data Source
Figure 1
Figure 2A~3
Figure 4A~5B
AI summary
Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.